Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features
COVID-19 치료용 면역조절제: 가능한 작용 기전 및 면역병리학적 특징
Review
[키워드] ACE2
acute respiratory distress
acute respiratory distress syndrome
acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
Analysis
angiotensin
Angiotensin-converting enzyme
Anosmia
antagonists
applied
ARDS
blood vessel
body aches
cause
clinical trial
clinical trials
coronavirus
coronavirus disease
Coronavirus disease 2019
Coronavirus disease 2019 (COVID-19)
COVID-19
COVID-19 case
COVID-19 patient
COVID-19 patients
COVID-19 treatment
Critical
critical patients
cytokine
Cytokine storm
Cytokines
demonstrated
described
drug
drugs
dry cough
Endothelial cell
endothelial cells
excessive secretion
feature
Fever
Health Organization
immune system
immunomodulatory
immunopathology
immunosuppressive agent
Immunosuppressive agents
incidence
include
Infection
Inflammatory responses
interleukin
investigated
lead
Lungs
mAbs
mechanical ventilator
mechanism
mechanism of action
medication
membrane
mitigate
modulating
monoclonal antibodies
monoclonal antibody
mortality rates
new virus
Novel coronavirus
overproduction
oxygen
Oxygen therapy
pandemic
pathophysiology
Patient
patients
penetrate
Physicians
pro-inflammatory factors
receptor
reduce mortality
researchers
respiratory
respiratory distress
Respiratory distress syndrome
SARS-CoV-2
severe acute respiratory syndrome Coronavirus
signaling pathway
signaling pathways
stimulate
Support
Symptom
syndrome
the disease
therapeutic compound
treat
triggering
virus
World Health Organization
Wuhan
Wuhan, China
[DOI] 10.1007/s11010-021-04325-9 PMC 바로가기 [Article Type] Review
[DOI] 10.1007/s11010-021-04325-9 PMC 바로가기 [Article Type] Review